Dren Bio, Sanofi Forge $1.8B B‑Cell Therapy Deal with US Co‑Promote Option
Dren Bio, Inc. announced a strategic collaboration with Sanofi (NASDAQ: SNY) to discover and develop...
Dren Bio
Sanofi to Acquire DR-0201 for $600 Million to Advance Myeloid Cell Engager
Sanofi (EPA: SAN, NASDAQ: SNY) announced plans to acquire DR-0201, a bispecific myeloid cell engager...
Novartis Partners with Dren Bio to Develop Next-Generation Cancer Therapies
Novartis (NYSE: NVS), a leading Swiss pharmaceutical company, has entered into a strategic collaboration with...